Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells

Leukemia Research

Volumn 39, Issue 4, 2015, Pages 445-452

  Tsubaki, Masanobu ^a   Takeda, Tomoya ^a   Ogawa, Naoki ^a,b   Sakamoto, Kotaro ^a   Shimaoka, Hirotaka ^a   Fujita, Arisa ^a   Itoh, Tatsuki ^a   Imano, Motohiro ^c   Ishizaka, Toshihiko ^b   Satou, Takao ^c   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b Sakai City Medical Center   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug resistance; Multiple myeloma; Survivin; Vincristine

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; FUMARIC ACID DIMETHYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE B; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; TRANSCRIPTION FACTOR RELA; VINCRISTINE; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MAPK1 PROTEIN, HUMAN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG RESISTANCE; GENETICS; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPLE MYELOMA; NF-KAPPA B; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 84925126126     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.01.016     Document Type: Article

References (29)

1. Tai Y.T., Podar K., Mitsiades N., Lin B., Mitsiades C., Gupta D., et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 2003, 101:2762-2769.
2. Tohnya T.M., Figg W.D. Immunomodulation of multiple myeloma. Cancer Biol Ther 2004, 3:1060-1061.
3. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
4. Katz B.Z. Adhesion molecules - the lifelines of multiple myeloma cells. Semin Cancer Biol 2010, 20:186-195.
5. Tsubaki M., Satou T., Itoh T., Imano M., Komai M., Nishinobo M., et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leuk Res 2012, 36:1315-1322.
6. Richardson P., Mitsiades C., Schlossman R., Ghobrial I., Hideshima T., Chauhan D., et al. The treatment of relapsed and refractory multiple myeloma. Hematol Am Soc Hematol Educ Progr 2007, 1:317-323.
7. Reece D.E1, Leitch H.A., Atkins H., Voralia M., Canning L.A., LeBlanc R., et al. Treatment of relapsed and refractory myeloma. Leuk Lymphoma 2008, 49:1470-1485.
8. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21.
9. Eckford P.D., Sharom F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009, 109:2989-3011.
10. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007, 28:1133-1139.
11. Kojima H., Iida M., Yaguchi Y., Suzuki R., Hayashi N., Moriyama H., et al. Enhancement of cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg 2006, 132:682-685.
12. Zhang M., Mukherjee N., Bermudez R.S., Latham D.E., Delaney M.A., Zietman A.L., et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 2005, 64:293-302.
13. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
14. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58:5315-5320.
15. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Investig 2004, 114:1117-1127.
16. Tsubaki M., Komai M., Itoh T., Imano M., Sakamoto K., Shimaoka H., et al. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leuk Res 2014, 38:121-130.
17. Que W., Chen J., Chuang M., Jiang D. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS 2012, 120:195-203.
18. Cirstea D., Hideshima T., Rodig S., Santo L., Pozzi S., Vallet S., et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010, 9:963-975.
19. Zhang H.R., Chen J.M., Zeng Z.Y., Que W.Z. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res 2013, 41:584-595.
20. Kisucká J., Barancík M., Bohácová V., Breier A. Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen Physiol Biophys 2001, 20:439-444.
21. Meinel F.G., Mandl-Weber S., Baumann P., Leban J., Schmidmaier R. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance. Mol Cancer Ther 2010, 9:300-310.
22. Tsubaki M., Komai M., Itoh T., Imano M., Sakamoto K., Shimaoka H., et al. Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs. Eur J Cancer 2013, 49:3708-3717.
23. Ahn K.C., Choi J.Y., Kim J.S., Hwang S.G., Kim W.J., Park J.K., et al. ICAM-3 endows anticancer drug resistance against microtubule-damaging agents via activation of the ICAM-3-AKT/ERK-CREB-2 pathway and blockage of apoptosis. Biochem Biophys Res Commun 2013, 441:507-513.
24. Galski H., Sivan H., Lazarovici P., Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk Res 2006, 30:1151-1158.
25. Simonian P.L., Grillot D.A., Nuñez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997, 90:1208-1216.
26. Cheung C.H., Chen H.H., Kuo C.C., Chang C.Y., Coumar M.S., Hsieh H.P., et al. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 2009, 8:43.
27. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 1999, 10(Suppl. 6):53-59.
28. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000, 247:521-534.
29. Tulpule A., Sherrod A., Dharmapala D., Young L.L., Espina B.M., Sanchez M.N., et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res 2002, 26:121-127.